Gilead says FDA lifts partial clinical hold on MDS and AML magrolimab studies
April 11, 2022 at 16:50 PM EDT
The U.S. Food and Drug Administration has lifted a partial clinical hold on studies evaluating magrolimab in combination with azacitidine, Gilead Sciences Inc. said Monday.
